Location

Rochester, Minnesota

Contact

Ma.Wen@mayo.edu Clinical Profile

SUMMARY

Wen Wee Ma, M.B.B.S., conducts clinical and translational research in developing anti-cancer agents in the clinic and laboratory for patients with refractory solid tumors and gastrointestinal cancers.

Dr. Ma collaborates extensively with scientists and biotech partners in designing and executing first-in-human clinical trials and clinical studies with translational endpoints. His research has led to the launch of phase II and III clinical trials, and contributed to the regulatory approval of nab-paclitaxel for treating pancreatic cancer and uridine triacetate for severe chemotherapy toxicity.

Focus areas

  • Developmental therapeutics. Dr. Ma is part of the Early Cancer Therapeutics-Phase I Program at Mayo Clinic and has been the principal investigator for a number of investigator-initiated and pharma-sponsored phase I trials evaluating first-in-human agents and novel combinations. The research focuses on the understanding of the effects of the novel therapeutics in human patients with cancer.
  • Novel therapeutics in pancreatic cancer. Dr. Ma's research in pancreatic cancer focuses on targeting the tumor microenvironment. He co-leads a research consortium consisting of a multidisciplinary team from the United States, Ireland and Northern Ireland. The group currently investigates strategies that will attenuate the stromal barrier to enhance the efficacy of existing therapeutics.

Significance to patient care

Cancer is a highly heterogeneous and complex disease. Even though precision medicine is becoming a reality in cancer therapy, many new anti-cancer drugs are effective in subsets of patients and treatment resistance can develop relatively rapidly. Early clinical-stage therapeutics research can further the understanding of the effects of new drugs in humans and on the cancer, and accelerate the availability of new effective treatment for patients with cancer.

Professional highlights

  • Member, National Comprehensive Cancer Network Clinical Practice Guidelines for Pancreatic Adenocarcinoma Panel, 2011-2016
  • Recipient, Cancer and Leukemia Group B Alliance Investigator Award, 2009
  • Recipient, Young Investigator Award, American Society of Clinical Oncology, 2007

PUBLICATIONS

See my publications

PROFESSIONAL DETAILS

Primary Appointment

  1. Senior Associate Consultant, Division of Medical Oncology, Department of Oncology

Academic Rank

  1. Professor of Oncology

EDUCATION

  1. Fellow - Clinical and Research Fellowship, Medical Oncology & Hematology Johns Hopkins University School of Medicine
  2. Certificate - The Science of Clinical Investigation Johns Hopkins University School of Medicine and School of Public Health
  3. Internship/Residency - Internal Medicine Johns Hopkins Bayview Medical Center
  4. Residency - Internal Medicine National University Hospital of Singapore
  5. Internship Ministry of Health - Singapore
  6. MBBS University of Sydney
.
BIO-20305148

Mayo Clinic Footer